Shanghai, China, September 19, 2024 — The ENO™ 3T MR-conditional pacemaker system (ENO™), developed for patients with bradycardia who may require 3T and 1.5T full-body MRI scans, has successfully completed its first batch of clinical implantations in China, in locations including Shanghai, Inner Mongolia, and Hebei Provinces. The ENO™ system has received positive feedback from several experts, marking its successful introduction into clinical practice in China.
Bradycardia, characterized by a heart rate of less than 60 beats per minute, can result in symptoms ranging from dizziness and fatigue to more serious conditions such as syncope or temporary vision loss. For patients at risk, pacemaker implantation may be recommended to restore normal heart function.
Professor Ruogu Li from Shanghai Chest Hospital, who led one of the first ENO™ implantations, emphasized the increasing need for 3T MRI-compatible pacemakers, particularly among elderly patients who may require imaging for other conditions. ENO™'s AutoMRI™ technology simplifies the MRI process, allowing patients to undergo multiple scans within 10 days without needing repeated adjustments. This not only ensures patient safety but also reduces the workload on healthcare providers, improving efficiency for both patients and clinicians.
Previously, the MR-conditional pacemaker system, comprising the ENO™ pacemaker and Vega™ pacing leads, was studied in a global CAPRI trial, which spanned 29 clinical centers worldwide, including sites in China. Professor Meixiang Xiang from the Second Affiliated Hospital Zhejiang University School of Medicine led the Chinese part of the study, confirming the system’s safety and effectiveness for Chinese patients. This research provided critical data that supported the system's approval and market launch in China. The findings were published in 2023 in European Radiology, a leading journal in medical imaging research.
About MicroPort CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through our long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Our state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic.
For more information, please refer to www.microport.com